Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Milk Thistle (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Laboratory / Animal / Preclinical Studies

    Research studies conducted in the laboratory have investigated the properties of silymarin or its isomer silybin using cell lines and animal models. Other substances in milk thistle have not been extensively studied.

    Several research studies have investigated the effects of silymarin or silybin in a noncancer context. These studies have tested silymarin or silybin:

    Recommended Related to Cancer

    Introduction

    Many of the medical and scientific terms used in this summary are found in the NCI Dictionary of Genetics Terms. When a linked term is clicked, the definition will appear in a separate window. Many of the genes described in this summary are found in the Online Mendelian Inheritance in Man (OMIM) database. When OMIM appears after a gene name or the name of a condition, click on OMIM for a link to more information. There are several hereditary syndromes that involve endocrine or neuroendocrine glands,...

    Read the Introduction article > >

    • In healthy animal liver and kidney cells.
    • As a prophylaxis against toxic chemicals.
    • In stimulating detoxification pathways (enzyme concentrations and activity).
    • For antioxidant properties.

    Silymarin or silybin has also been investigated in cancer models. The effects of silymarin and/or silybin have been investigated in prostate (DU 145, LNCaP, PC-3),[1,2,3,4,5,6]breast (MDA-MB 468, MCF-7),[7,8,9]hepatic (HepG2),[10,11] epidermoid (A431),[11]colon (Caco-2),[12]ovarian (OVCA 433, A2780),[13]histiocytic lymphoma (U-937),[14] and leukemia (HL-60) [15,16]cells. In animal tumor models, tongue cancer,[17] skin cancer,[18,19,20,21,22,23]bladder cancer,[24] and adenocarcinoma of the colon [25,26] and small intestine [26] have been investigated. These studies have tested the ability of silymarin or silibinin to:

    • Mitigate the toxicity associated with chemotherapy agents.
    • Enhance the efficacy of chemotherapy agents.
    • Inhibit the growth of cancer cell lines and inhibit tumor initiation or tumor promotion.

    Although many of these studies have produced encouraging results, none of the findings have been replicated in human clinical trials.

    Laboratory data suggest that silymarin and silybin protect the liver from damage induced by toxic chemicals. Animal studies have found that liver cells treated with silybin and then exposed to toxins do not incur cell damage or death at the same rate as liver cells that are not treated with silybin. This finding suggests that silybin can prevent toxins from entering the cell or effectively exports toxins out of the cell before damage ensues.[11,27,28,29,30,31] Alternatively, this may be related to the effect of silymarin on detoxification systems. In vitro data have shown silybin to stimulate and/or inhibit phase I detoxification pathways in silybin-treated human liver cells. However, this effect was found to be dose-dependent, and these levels are not physiologically attainable with the current manufacturer dose recommendations.[32,33]

    1 | 2 | 3 | 4
    1 | 2 | 3 | 4
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    New! I AM Not Cancer Facebook Group
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article